High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients.
BACKGROUND
Chemokines and chemokine receptors not only have significant roles in cancer metastasis and tumorigenesis but also act as antitumour agents. The interaction between the Crk-like adaptor protein (CrkL), which is encoded by the CRKL gene, and non-receptor tyrosine kinase c-ABL is reported to transform many cells into malignant cells. We examined the effects of CC chemokine receptor 7 (CCR7), CCR7 ligands and CrkL and c-ABL in lung adenocarcinoma.


METHODS
One hundred and twenty patients with lung adenocarcinoma were included in this historical cohort analysis. We examined CCR7 and CCR7 ligands and CrkL and c-ABL mRNA expressions in surgically resected lung adenocarcinoma specimens and evaluated their contribution to prognosis, and the relationship with epidermal growth factor receptor (EGFR) and TP53 mutations.


RESULTS
High CCR7 mRNA expressions indicated better prognoses than those of the groups with low CCR7 mRNA expressions (P=0.007, HR=2.00, 95% CI of ratio: 1.22 -3.31). In lung adenocarcinoma, CrkL and c-ABL mRNAs were related to CCR7 mRNA expression (P<0.0001). CrkL and c-ABL mRNA expressions were influenced by EGFR mutations. A high expression of CCL19 was a good prognostic factor of lung adenocarcinoma.


CONCLUSIONS
We propose that CCR7 and CCL19 are clinically good prognostic factors and that CCR7 is strongly related to CrkL and c-ABL kinase mRNA expression in lung adenocarcinoma.
Department of Thoracic Disease, Chiba Cancer Center, 662-2 Nitona-cho, Chuo-ku, Chiba 260-8717, Japan. mitakura@chiba-cc.jp
M
M
Itakura
Y
Y
Terashima
M
M
Shingyoji
S
S
Yokoi
M
M
Ohira
H
H
Kageyama
Y
Y
Matui
Y
Y
Yoshida
H
H
Ashinuma
Y
Y
Moriya
H
H
Tamura
K
K
Harigaya
K
K
Matushima
T
T
Iizasa
A
A
Nakagawara
H
H
Kimura
D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics; D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality* / Q000601:surgery; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D054415:Chemokine CCL19 / Q000096:biosynthesis* / Q000235:genetics; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000235:genetics; D011379:Prognosis; D016315:Proto-Oncogene Proteins c-abl / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis; D054400:Receptors, CCR7 / Q000235:genetics / Q000378:metabolism*; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
D048868:Adaptor Proteins, Signal Transducing; D014408:Biomarkers, Tumor; C515460:CCL19 protein, human; C082869:CRKL protein; D054415:Chemokine CCL19; D009687:Nuclear Proteins; D012333:RNA, Messenger; D054400:Receptors, CCR7; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C512478:EGFR protein, human; D066246:ErbB Receptors; D016315:Proto-Oncogene Proteins c-abl